Abstract

Objectives

Most cost-effectiveness analyses assume that a drug’s price remains unchanged after launch. Because prices typically change, this assumption can distort cost-effectiveness projections. Limited data on how prices change over a drug’s life cycle have limited the inclusion of dynamic pricing assumptions. This study characterized changes in drug prices after launch and before loss of market exclusivity.

Methods

We analyzed inflation-adjusted price data for 32 brand-name drugs that contribute substantially to US healthcare spending. We developed 2 regression models: (1) an ordinary least squares regression model to estimate average annual price changes after launch and (2) a linear mixed-effects regression to project how prices change over time. We identified independent factors potentially influencing price changes based on a literature review. We selected factors for model inclusion based on Akaike Information Criterion improvements. Net price data came from SSR Health.

Results

The average inflation-adjusted mean annual drug price change was −4.7% (median: −2.4%). The ordinary least squares model predicted negative mean annual price changes for all combinations of drug characteristics except for drugs with Medicare-protected class designations (P value the mixed-effects model indicated that price change rates tend to moderate with more time since launch.

Conclusions

For large-market branded drugs, inflation-adjusted prices often decline after launch and before loss of market exclusivity. Empirical modeling helps to refine projections based on observable characteristics, thus facilitating incorporation of dynamic pricing into cost-effectiveness analyses.